Cargando…

Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19

The corona virus disease 2019 (COVID-19) global pandemic has had an unprecedented and persistent impact on oncological practice, especially for patients with lung cancer, who are more vulnerable to the virus than the normal population. Indeed, the onset, progression, and prognosis of the two disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Ai, Yanling, Wang, Hengyi, Zheng, Qiao, Li, Songtao, Liu, Jingwen, Huang, Ju, Tang, Jianyuan, Meng, Xiangrui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076709/
https://www.ncbi.nlm.nih.gov/pubmed/37033918
http://dx.doi.org/10.3389/fimmu.2023.1174184
_version_ 1785020192516997120
author Ai, Yanling
Wang, Hengyi
Zheng, Qiao
Li, Songtao
Liu, Jingwen
Huang, Ju
Tang, Jianyuan
Meng, Xiangrui
author_facet Ai, Yanling
Wang, Hengyi
Zheng, Qiao
Li, Songtao
Liu, Jingwen
Huang, Ju
Tang, Jianyuan
Meng, Xiangrui
author_sort Ai, Yanling
collection PubMed
description The corona virus disease 2019 (COVID-19) global pandemic has had an unprecedented and persistent impact on oncological practice, especially for patients with lung cancer, who are more vulnerable to the virus than the normal population. Indeed, the onset, progression, and prognosis of the two diseases may in some cases influence each other, and inflammation is an important link between them. The original chronic inflammatory environment of lung cancer patients may increase the risk of infection with COVID-19 and exacerbate secondary damage. Meanwhile, the acute inflammation caused by COVID-19 may induce tumour progression or cause immune activation. In this article, from the perspective of the immune microenvironment, the pathophysiological changes in the lungs and whole body of these special patients will be summarised and analysed to explore the possible immunological storm, immunosuppression, and immune escape phenomenon caused by chronic inflammation complicated by acute inflammation. The effects of COVID-19 on immune cells, inflammatory factors, chemokines, and related target proteins in the immune microenvironment of tumours are also discussed, as well as the potential role of the COVID-19 vaccine and immune checkpoint inhibitors in this setting. Finally, we provide recommendations for the treatment of lung cancer combined with COVID-19 in this special group.
format Online
Article
Text
id pubmed-10076709
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100767092023-04-07 Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19 Ai, Yanling Wang, Hengyi Zheng, Qiao Li, Songtao Liu, Jingwen Huang, Ju Tang, Jianyuan Meng, Xiangrui Front Immunol Immunology The corona virus disease 2019 (COVID-19) global pandemic has had an unprecedented and persistent impact on oncological practice, especially for patients with lung cancer, who are more vulnerable to the virus than the normal population. Indeed, the onset, progression, and prognosis of the two diseases may in some cases influence each other, and inflammation is an important link between them. The original chronic inflammatory environment of lung cancer patients may increase the risk of infection with COVID-19 and exacerbate secondary damage. Meanwhile, the acute inflammation caused by COVID-19 may induce tumour progression or cause immune activation. In this article, from the perspective of the immune microenvironment, the pathophysiological changes in the lungs and whole body of these special patients will be summarised and analysed to explore the possible immunological storm, immunosuppression, and immune escape phenomenon caused by chronic inflammation complicated by acute inflammation. The effects of COVID-19 on immune cells, inflammatory factors, chemokines, and related target proteins in the immune microenvironment of tumours are also discussed, as well as the potential role of the COVID-19 vaccine and immune checkpoint inhibitors in this setting. Finally, we provide recommendations for the treatment of lung cancer combined with COVID-19 in this special group. Frontiers Media S.A. 2023-03-23 /pmc/articles/PMC10076709/ /pubmed/37033918 http://dx.doi.org/10.3389/fimmu.2023.1174184 Text en Copyright © 2023 Ai, Wang, Zheng, Li, Liu, Huang, Tang and Meng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ai, Yanling
Wang, Hengyi
Zheng, Qiao
Li, Songtao
Liu, Jingwen
Huang, Ju
Tang, Jianyuan
Meng, Xiangrui
Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19
title Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19
title_full Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19
title_fullStr Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19
title_full_unstemmed Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19
title_short Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19
title_sort add fuel to the fire: inflammation and immune response in lung cancer combined with covid-19
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076709/
https://www.ncbi.nlm.nih.gov/pubmed/37033918
http://dx.doi.org/10.3389/fimmu.2023.1174184
work_keys_str_mv AT aiyanling addfueltothefireinflammationandimmuneresponseinlungcancercombinedwithcovid19
AT wanghengyi addfueltothefireinflammationandimmuneresponseinlungcancercombinedwithcovid19
AT zhengqiao addfueltothefireinflammationandimmuneresponseinlungcancercombinedwithcovid19
AT lisongtao addfueltothefireinflammationandimmuneresponseinlungcancercombinedwithcovid19
AT liujingwen addfueltothefireinflammationandimmuneresponseinlungcancercombinedwithcovid19
AT huangju addfueltothefireinflammationandimmuneresponseinlungcancercombinedwithcovid19
AT tangjianyuan addfueltothefireinflammationandimmuneresponseinlungcancercombinedwithcovid19
AT mengxiangrui addfueltothefireinflammationandimmuneresponseinlungcancercombinedwithcovid19